Israel Englander’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Israel Englander’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-100,043	Closed	-$4.8M	–	4870
2020 Q1	$4.8M	Sell	100,043 -521,123	-84%	-$24.2M	0.01%	1356
2019 Q4	$29.2M	Buy	621,166 +488,888	+370%	+$21.6M	0.04%	613
2019 Q3	$3.13M	Buy	132,278 +213	+0.2%	+$6.31K	﹤0.01%	2143
2019 Q2	$3.97M	Sell	132,065 -273,875	-67%	-$6.27M	0.01%	1949
2019 Q1	$9.09M	Sell	405,940 -6,126	-1%	-$132K	0.01%	1330
2018 Q4	$7.5M	Buy	412,066 +330,788	+407%	+$5.19M	0.01%	1305
2018 Q3	$1.47M	Sell	81,278 -168,009	-67%	-$1.99M	﹤0.01%	2650
2018 Q2	$2.48M	Sell	249,287 -421,975	-63%	-$2.91M	﹤0.01%	2256
2018 Q1	$3.56M	Buy	671,262 +226,565	+51%	+$1.62M	﹤0.01%	2001
2017 Q4	$3.78M	Sell	444,697 -187,060	-30%	-$2.3M	0.01%	1893
2017 Q3	$9.22M	Buy	631,757 +434,042	+220%	+$6.56M	0.01%	1300
2017 Q2	$3.71M	Buy	197,715 +151,737	+330%	+$3.42M	0.01%	1708
2017 Q1	$979K	Sell	45,978 -15,910	-26%	-$304K	﹤0.01%	2411
2016 Q4	$940K	Buy	+61,888	New	+$841K	﹤0.01%	2288

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Israel Englander's RARX Position: Q2 2020 in Review

Israel Englander sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 100,043 shares — an estimated $4.8M sold.

Israel Englander first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $29.2M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Israel Englander reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Israel Englander sold 100,043 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $4.8M.
Israel Englander first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
Israel Englander's Ra Pharmaceuticals, Inc. Common Stock position peaked at $29.2M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Millennium Management's 13F filing for Q2 2020, filed 14 Aug 2020.